Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 277

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 277
---
,205 $6,677 $2,808 (1)Cash paid for amounts included in the measurement of lease liabilities is included in change in lease liabilities in our condensed consolidated statement of cash flows. (2)Sublease income is included net within “Other income (expense)” in our condensed consolidated statements of operations. Rent received from our subtenant in excess of rent paid to the landlord is shared by paying the landlord 50% of the excess rent. The excess rent is considered a variable lease payment and the total estimated payments are being recognized as additional rent expense on a straight-line basis.The balance sheet classification of our operating lease liabilities was as follows (in thousands): September 30, 2025December 31, 2024Operating lease liabilities:Current portion of lease liabilities (included in other current liabilities)$4,199 $4,175 Long-term portion of lease liabilities23,985 26,388 Total operating lease liabilities$28,184 $30,563 

13

As of September 30, 2025, the maturities of our sublease income and operating lease liabilities were as follows (in thousands):Years ending December 31,Sublease IncomeOperating Lease Liabilities 2025 (remaining)$1,532 $1,739 20266,342 6,711 20276,564 6,654 20286,794 6,639 20297,031 6,483 Thereafter9,160 8,759 Total$37,423 36,985 Less:Present value adjustment (8,801)Total $28,184 The weighted average remaining lease term and the weighted average discount rate used to determine the operating lease liabilities were as follows: September 30, 2025December 31, 2024Weighted average remaining lease term5.4 years5.9 yearsWeighted average discount rate10.1%10.1%CommitmentsWe have entered into material purchase commitments with commercial manufacturers for the supply of HEPLISAV-B. As of September 30, 2025, our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B totaled $83.2 million, which are expected to be paid through 2029. In addition to the non-cancelable commitments included above, we have entered into contractual arrangements that obligate us to make payments to the contractual counterparties upon the occurrence of future events. In addition,